Aslıhan Karaer Tunçay

Aslıhan Karaer Tunçay

Auto-generated profile, based on publicly available information

Aslıhan Karaer Tunçay

Department of Chemistry, Faculty of Science

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2024 in ACS Omega
Verified
Journal Article
Open access
HKHande Karabıyık
Hande Karabıyık
ATAslıhan Karaer Tunçay
Aslıhan Karaer Tunçay
SISuleyman ILHAN
Suleyman ILHAN
HAHarika Atmaca
Harika Atmaca
HTHayati Türkmen
Hayati Türkmen
A series of aryl–isatin Schiff base derivatives (3a–d) and their piano-stool ruthenium complexes (4a–d) were synthesized and characterized via 1H and 13C NMR and Fourier transform infrared (FTIR) spectroscopy. In addition, the purity of all of the compounds (3a–c and 4a–d) was determined via elemental analysis. Complex 4d was analyzed using X-ray crystallography. An in vitro antiproliferative study of the compounds (3a–c and 4a–d) against human hepatocellular carcinoma (HEPG2), human breast cancer (MCF-7), human prostate cancer (PC-3), and human embryonic kidney (HEK-293) cells exhibited their considerable antiproliferative activity. 4d exhibited effective cytotoxicity against HEPG2 and MCF-7. It displayed higher cytotoxicity than the reference metallo-drug cisplatin. Moreover, the stability of 4d was studied via 1H NMR spectroscopy, and the binding model between 4d and DNA was investigated via ultraviolet–visible spectroscopy. The lipophilicity of the synthesized complexes was determined using an extraction method.

22 July 2025 in Applied Organometallic Chemistry
Verified
Journal Article
Closed access
ATAslıhan Karaer Tunçay
Aslıhan Karaer Tunçay
YGYonca Gungor
Yonca Gungor
HKHande Karabıyık
Hande Karabıyık
HKHulya Ayar Kayali
Hulya Ayar Kayali
HTHayati Türkmen
Hayati Türkmen

28 April 2026 in ACS Omega
Verified
Journal Article
Open access
ATAslıhan Karaer Tunçay
Aslıhan Karaer Tunçay
SISuleyman ILHAN
Suleyman ILHAN
HAHarika Atmaca
Harika Atmaca
HTHayati Türkmen
Hayati Türkmen
This study focuses on the synthesis, characterization, and anticancer activities of 1,10-phenanthroline-linked imidazolium salts (3) bearing different alkyl groups (methyl(a), butyl(b), octyl(c), dodecyl(d)) or benzyl (benzyl(e), 2,4,6-trimethylbenzyl(f)) groups. The synthesized salts were fully characterized using various analytical techniques, including UV–vis, 1H NMR, 13C NMR, FT-IR, and mass spectrometry. Their biological activities were evaluated against DU-145 (prostate cancer), MCF-7 (breast cancer), T98G (glioblastoma cancer), and the nontumorigenic HEK-293 (human embryonic kidney) cell lines. The most potent compound 3e exhibited a remarkable DNA binding constant (Kb = 1.66 ± 0.1 × 106 M–1), indicating a strong interaction with DNA. Additionally, molecular docking studies were performed to assess the interaction of 3e with key apoptotic and cell cycle regulatory proteins (Bcl-2, Bcl-xL, CDK1, and Cyclin B1), suggesting a potential mechanism for its anticancer activity. ADME-related analyses of the lead compound 3e were conducted, providing an initial pharmacokinetic profile to support its progression as a preclinical candidate. In cancer cell lines, mitochondrial morphology and integrity were evaluated at IC50 concentrations against compound 3e using Invitrogen MitoTracker stain. These findings highlight the dual role of 1,10-phenanthroline-linked imidazolium salts as DNA-interacting agents and selective anticancer compounds, paving the way for their further development as targeted chemotherapeutic candidates.

30 January 1990 in ChemInform
Verified
Journal Article
Closed access
PDF file
RMR. M. Moriarty
R. M. Moriarty
RVR. K. Vaid
R. K. Vaid
THT. E. Hopkins
T. E. Hopkins
BVB. K. Vaid
B. K. Vaid
ATA. Tuncay
A. Tuncay